Quince therapeutics presents preclinical data at oi 2022 demonstrating potential of a targeted anabolic for accelerated bone healing of osteogenesis imperfecta fractures

South san francisco, calif.--(business wire)---- $qncx--quince therapeutics, inc. (nasdaq: qncx), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, today presented preclinical data at the 14th international conference on osteogenesis imperfecta (oi 2022) demonstrating the potential of its novel targeted therapeutic nov004 to treat fracture in osteogenesis imperfecta (oi) by promoting accelerated increases in bone density, strength, and heali
QNCX Ratings Summary
QNCX Quant Ranking